Navidea and Macrophage Therapeutics to Provide Development Program Update
May 03 2016 - 7:00AM
Business Wire
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) announces a
conference call on Thursday, May 5, 2016 at 4:30 p.m. ET to further
update the market on its Manocept™ macrophage targeting programs
for immunodiagnostic and immunotherapeutic applications.
As mentioned on our previous call, we are eager to keep an open
channel of discussion with investors regarding the important
developments with the Manocept technology. We will devote a
substantial portion of the call to Q&A as we want to make
certain we address the subjects that are important to investors. We
plan to continue discussing the progress of this promising
technology during regularly scheduled Macrophage Therapeutics
update calls.
Conference Call Details
Investors and the public are invited to access the live audio
webcast through the link below. Participants who would like to ask
questions during the question and answer session must participate
by telephone also. Participants are encouraged to log-in and/or
dial-in fifteen minutes before the conference call begins. The
webcast replay is expected to be available on our investor website,
http://ir.navidea.com, approximately two to four hours after the
live event.
Event: Navidea and Macrophage Therapeutics Manocept™
Program Update Call Date/Time: Thursday, May 5, 2016 at 4:30 p.m.
ET Webcast Link:
http://edge.media-server.com/m/p/iugtsbk3/lan/en
Dial-in Number – US: (855) 897-5884 Dial in Number – Int’l: (720)
634-2940 Participant Passcode: 5852350 Replay
A webcast replay will be available on the
Investor Relations section of our website at http://ir.navidea.com
for 30 days.
About Manocept CD206 Immunotargeting Platform for
Therapeutics Development
Manocept™ CD206 Immunotargeting Platform is a proprietary
mannose-containing, receptor-directed technology platform designed
to engineer novel, synthetic receptor targeted imaging agents and
therapeutics for cancer and other diseases. Manocept’s unique
structural and molecular properties enable the design of novel
immuno-constructs that selectively target and bind to CD206
(mannose receptor) and other C-type Lectins found on activated,
disease-associated macrophages and tumor associated macrophages
(TAMs). The Manocept CD206 Immunotargeting Platform provides a
novel and valuable approach to the design of drug molecules
targeting CD206 disease-associated macrophages for therapeutic
purposes.
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a
biopharmaceutical company focused on the development and
commercialization of precision immunodiagnostic agents and
immunotherapeutics. Navidea is developing multiple
precision-targeted products and platforms including Manocept™ and
NAV4694 to help identify the sites and pathways of undetected
disease and enable better diagnostic accuracy, clinical
decision-making, targeted treatment and, ultimately, patient care.
Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s
first commercial product from the Manocept platform, was approved
by the FDA in March 2013 and in Europe in November 2014. The
development activities of the Manocept immunotherapeutic platform
will be conducted by Navidea in conjunction with its subsidiary,
Macrophage Therapeutics. Navidea’s strategy is to deliver superior
growth and shareholder return by bringing to market novel products
and advancing the Company’s pipeline through global partnering and
commercialization efforts. For more information, please visit
www.navidea.com.
About Macrophage Therapeutics
Macrophage Therapeutics, Inc., a subsidiary of Navidea
Biopharmaceuticals, Inc. (NAVB), is developing therapeutics using
the patented Manocept immunotherapy platform licensed from Navidea
to target over-active macrophages implicated in cancer,
cardiovascular, central nervous system, autoimmune, antiviral, and
skin diseases. Manocept specifically targets CD206, or the mannose
receptor prevalent on over-active macrophages. The technology
enables highly specific targeted delivery of active (either
existing or yet to be developed) agents that can modulate the
activity of over-active macrophages that have been implicated in
many diseases. Targeted delivery should significantly enhance a
given compound’s efficacy and safety.
The Private Securities Litigation Reform Act of 1995 (the Act)
provides a safe harbor for forward-looking statements made by or on
behalf of the Company. Statements in this news release, which
relate to other than strictly historical facts, such as statements
about the Company’s plans and strategies, expectations for future
financial performance, new and existing products and technologies,
anticipated clinical and regulatory pathways, and markets for the
Company’s products are forward-looking statements within the
meaning of the Act. The words “believe,” “expect,” “anticipate,”
“estimate,” “project,” and similar expressions identify
forward-looking statements that speak only as of the date hereof.
Investors are cautioned that such statements involve risks and
uncertainties that could cause actual results to differ materially
from historical or anticipated results due to many factors
including, but not limited to, the Company’s continuing operating
losses, uncertainty of market acceptance of its products, reliance
on third party manufacturers, accumulated deficit, future capital
needs, uncertainty of capital funding, dependence on limited
product line and distribution channels, competition, limited
marketing and manufacturing experience, risks of development of new
products, regulatory risks and other risks detailed in the
Company’s most recent Annual Report on Form 10-K and other
Securities and Exchange Commission filings. The Company undertakes
no obligation to publicly update or revise any forward-looking
statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160503005719/en/
Navidea BiopharmaceuticalsInvestors &
MediaSharon Correia, 978-655-2686Senior Director, Corporate
Communications
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Apr 2023 to Apr 2024